Feb 05, 2026
3 min read
US dual-action presbyopia green light eye drops that restore vision for up to 10 hours with just daily application.
Ophthalmologists Wary of Eye Drops That Promise to Remove Glasses and Contact Lenses: 'More Information Needed'
US gives the green light to bilateral presbyopia eye drops that restore up to 10 hours of near vision with one daily application.
The Spanish Society of Ophthalmology recalls that the molecules are not new and warns of side effects such as headaches or irritation.
Ophthalmologists criticized optometrists for prescribing glasses and contact lenses: "They can improve vision, but they can't diagnose."
The appearance of eye drops recently approved in the United States, which eliminate the effects of presbyopia or eye strain after one daily application, has prompted a reaction from the Spanish Society of Ophthalmology (SEO), which calls for caution.The scientific community states that the approved drugs are not new molecules, "but active substances that have been known in ophthalmology for decades."
Yuvezzi, a therapy developed by biotech company Tenpoint Therapeutics, is one of the latest eye drops to just receive FDA approval for sale and is the first dual-action eye drop that restores near vision for up to 10 hours, according to the pharmaceutical company.Previously, Lenz Therapeutics developed Vizz, which is in the process of authorization in other markets, such as Canada or China, and has similar effects.
The FDA gave the green light to Uvezi following the successful completion of a two-phase study. These clinical trials followed participants for 12 months and more than 72,000 days of treatment, representing the longest-term safety study conducted at the Presidential Center to date.The drug is active for 30 minutes and can maintain its effect for up to 10 hours with one drop per day in each eye.
Despite approval in the United States, they currently do not have authorization in Europe, SEO reminds.For this reason, they recommend "wisdom and caution in the proposal of these new treatments. It will be necessary to obtain more information from independent clinical studies with medium and long-term follow-up, which will allow a more accurate understanding of their real effect, safety and profile of candidate patients."
Presbyopia is a physiological condition associated with eye aging and its treatment should always be under the supervision of an ophthalmologist, who can provide individual information on the available options (optical, pharmacological or surgical) depending on the characteristics of each patient, experts say.Myopia (37%), astigmatism (36%) and presbyopia (31.2%) are the main eye pathologies diagnosed in Spain.
Ophthalmologists insist: drugs are not completely new molecules, but active ingredients known for a long time.Among them, they state, are parasympathomimetic muscarinic agonists such as pilocarpine, acyclidine, or carbachol, which cause miosis (constriction of the pupil) and ciliary muscle contraction.This mechanism allows the depth of focus to increase for a few hours, which improves near vision in patients with presbyopia, although it also induces a temporary nearsightedness effect.
In recent years, many eye drops containing these active ingredients (alone or in combination with other drugs) have been approved in the United States, such as pilocarpine, low concentrations of acetylene, or newer compounds that include carbachol and bromonidine."They all share similar mechanisms of action, and so do similar impact profiles," says SEO.
Among the adverse effects described with this treatment are headache, ocular hyperemia, irritation and visual discomfort resulting from miosis." Although brimonidine is a well-known and well-accepted drug in the treatment of glaucoma, carbachol is an agent with a strong pharmacological action on muscarinic and nicotinic receptors, whose local ophthalmic use was abandoned in the past due to side effects and the possibility, described in the scientific literature, of complications in some cases associated with persistent muscle spasms andretinal detachment," added the expert.
Subscribe to continue reading
- AP-7 reopens starting this Wednesday only to bypass Intercity and Renfe buses
- Catalonia, with 44,000 new cases of cancer and 18,000 deaths in 2025, integrates molecular blood analysis to treat lung cancer
- Two famous paleontologists from America are already working in Catalonia: "With Trump, the study of human evolution is banned.
- STOM LOOKORO, LOOKING: The last hour of the most beautiful and the red light in Andallia
– Josefina Castellví, the biologist who fell in love with Antarctica, died
- Laura Mezquita, oncologist: "Radon, another cause of lung cancer, can be found in every home, it must be measured.
- Latest news about the Gelida train accident, live |Train drivers are seeking a written letter from Aif guaranteeing safety to continue the service
- Increase in measles cases forces to strengthen measures: Catalonia urges people born between 1978 and 1980 to be vaccinated and will carry out PCR "when there is the least doubt"
